Through integrated proteomic, phosphoproteomic, and transcriptomic analyses, Yuen Lam Dora Ng et al identified CDK6 upregulation as a druggable target in lenalidomide-resistant MM.[34] Daratumumab, a CD38-targeted monoclonal antibody, primarily exerts antitumor effects through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. This evidence concerns the gene CD38 and Miyoshi myopathy.